![Sebastian Inger](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Jeppe Ragnar Andersen | M | - |
NBCD A/S
![]() NBCD A/S BiotechnologyHealth Technology NBCD A/S is based in Herlev, Denmark. Part of SIPCO Holdings Ltd., NBCD A/S is a contract research organization (CRO) dedicated to clinical drug development and research in osteoarthritis. The Danish company specializes in designing and executing clinical trials for both pain and disease-modifying osteoarthritis drugs (DMOAD) compounds. NBCD is known for their expertise in mitigating placebo response and designing osteoarthritis studies. The company supports biotech and pharmaceutical clients in advancing osteoarthritis compounds through all clinical development phases. With over 25 years of experience in osteoarthritis biomarkers and clinical trials, NBCD combines preclinical and clinical research to provide a faster and smarter evaluation of the potential clinical viability of drug candidates. The company was founded in 1989, and the CEO is Jeppe Ragnar Andersen. | - |
Daniel José López-Cruz | M | 59 |
NBCD A/S
![]() NBCD A/S BiotechnologyHealth Technology NBCD A/S is based in Herlev, Denmark. Part of SIPCO Holdings Ltd., NBCD A/S is a contract research organization (CRO) dedicated to clinical drug development and research in osteoarthritis. The Danish company specializes in designing and executing clinical trials for both pain and disease-modifying osteoarthritis drugs (DMOAD) compounds. NBCD is known for their expertise in mitigating placebo response and designing osteoarthritis studies. The company supports biotech and pharmaceutical clients in advancing osteoarthritis compounds through all clinical development phases. With over 25 years of experience in osteoarthritis biomarkers and clinical trials, NBCD combines preclinical and clinical research to provide a faster and smarter evaluation of the potential clinical viability of drug candidates. The company was founded in 1989, and the CEO is Jeppe Ragnar Andersen. | - |
Celine Infeld | F | - |
NBCD A/S
![]() NBCD A/S BiotechnologyHealth Technology NBCD A/S is based in Herlev, Denmark. Part of SIPCO Holdings Ltd., NBCD A/S is a contract research organization (CRO) dedicated to clinical drug development and research in osteoarthritis. The Danish company specializes in designing and executing clinical trials for both pain and disease-modifying osteoarthritis drugs (DMOAD) compounds. NBCD is known for their expertise in mitigating placebo response and designing osteoarthritis studies. The company supports biotech and pharmaceutical clients in advancing osteoarthritis compounds through all clinical development phases. With over 25 years of experience in osteoarthritis biomarkers and clinical trials, NBCD combines preclinical and clinical research to provide a faster and smarter evaluation of the potential clinical viability of drug candidates. The company was founded in 1989, and the CEO is Jeppe Ragnar Andersen. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Denemarken | 3 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Sebastian Inger
- Persoonlijk netwerk